Elizabeth Murphy Lilly - 31 Mar 2026 Form 4 Insider Report for APOGEE ENTERPRISES, INC. (APOG)

Reporting relationship: Director
Issuer ticker: APOG
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2026, 17:16:45 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ David Wright Walstrom Attorney-in-Fact for Elizabeth Murphy Lilly

Key filing fact

Elizabeth Murphy Lilly filed Form 4 for APOGEE ENTERPRISES, INC. (APOG) on 01 Apr 2026.

Key facts

This page summarizes Elizabeth Murphy Lilly's Form 4 filing for APOGEE ENTERPRISES, INC. (APOG).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2026, 17:16.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001799209 Primary reporting owner

Lilly Elizabeth Murphy

Relationship: Director
Address: C/O APOGEE ENTERPRISES, INC., 4400 WEST 78TH STREET, SUITE 520, MINNEAPOLIS
Signature: /s/ David Wright Walstrom Attorney-in-Fact for Elizabeth Murphy Lilly
Signature date: 01 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APOG transaction Derivative

Deferred Restricted Stock Units

Award

Transaction value
Shares: +55
Change %: +0.8%
Price: $33.54^*
Shares after: 6,900
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Settled 1-for-1.

Footnote F2

Additional deferred restricted stock units were allocated pursuant to a dividend equivalent reinvestment feature of the 2019 Non-Employee Director Stock Plan.

Footnote F3

The deferred restricted stock units were allocated under the 2019 Non-Employee Director Stock Plan. The deferred restricted stock units will be settled in shares of common stock following the director's termination from the Board in accordance with the election of the reporting person, or following the occurrence of other events specified in the Plan.